Fresenius SE KGaA Beheer

Hoe is Michael Sen's beloning veranderd ten opzichte van Fresenius SE KGaA's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-€479m
Jun 30 2024	n/a	n/a	€721m
Mar 31 2024	n/a	n/a	€420m
Dec 31 2023	€7m	€2m	€353m
Sep 30 2023	n/a	n/a	€2b
Jun 30 2023	n/a	n/a	€555m
Mar 31 2023	n/a	n/a	€952m
Dec 31 2022	€5m	€1m	€1b
Sep 30 2022	n/a	n/a	€1b
Jun 30 2022	n/a	n/a	€2b
Mar 31 2022	n/a	n/a	€2b
Dec 31 2021	€2m	€755k	€2b

Compensatie versus markt: De totale vergoeding ($USD 7.33M ) Michael } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 4.77M ).

Compensatie versus inkomsten: De vergoeding van Michael is gestegen terwijl het bedrijf verliesgevend is.

CEO

Michael Sen (56 yo)

3.6yrs

Tenure

€6,992,000

Compensatie

Mr. Michael Sen is Chairman of the Supervisory Board at Fresenius Medical Care AG from July 14, 2023. He is Chief Executive Officer & President of Fresenius Management SE at Fresenius SE & Co. KGaA since O...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Sen	CEO, President & Chairman of Management Board of Fresenius Management SE	3.6yrs	€6.99m	geen gegevens
Sara Hennicken	CFO & Member of the Management Board - Fresenius Management SE	2.2yrs	€2.39m	geen gegevens
Pierluigi Antonelli	Member of Management Board of Fresenius Management SE & CEO of Fresenius Kabi	1.7yrs	€3.12m	geen gegevens
Michael Moser	Member of Management Board of Fresenius Management SE	1.3yrs	€1.62m	geen gegevens
Robert Moller	Member of the Management Board of Fresenius Management SE	1.2yrs	€1.42m	geen gegevens
Nick Stone	Senior VP of Investor Relations & Head of Investor Relations - Fresenius Management SE	less than a year	geen gegevens	geen gegevens
Matthias Link	Senior Vice President Corporate Communications	no data	geen gegevens	geen gegevens
Sebastian Schlagwein	Head of Group ESG	no data	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

49.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van FRE wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gerd Krick	Honorary Chairman of Supervisory Board	3.5yrs	€219.00k	geen gegevens
Michael Diekmann	Independent Deputy Chairman of the Supervisory Board	9.5yrs	€320.00k	geen gegevens
Frank Appel	Member of the Supervisory Board	3.5yrs	€210.00k	geen gegevens
Wolfgang Kirsch	Independent Chairman of Supervisory Board	4.8yrs	€560.00k	geen gegevens
Grit Genster	Independent Deputy Chairperson of the Supervisory Board	4.5yrs	€310.00k	geen gegevens
D. Albrecht	Independent Member of Supervisory Board	13.8yrs	€180.00k	geen gegevens
Iris Loew-Friedrich	Independent Member of Supervisory Board	8.5yrs	€180.00k	geen gegevens
Susanne Zeidler	Independent Member of the Supervisory Board	3.5yrs	€290.00k	geen gegevens
Frauke Lehmann	Independent Member of Supervisory Board	8.5yrs	€180.00k	geen gegevens
Oscar De Paco	Independent Member of Supervisory Board	8.5yrs	€180.00k	geen gegevens
Bernd Behlert	Independent Member of Supervisory Board	6.2yrs	€215.00k	geen gegevens
Christoph Zindel	Independent Member of Supervisory Board	2.5yrs	€220.00k	geen gegevens

5.5yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van FRE wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).

Fresenius SE KGaA Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

PAI Mid-Market Fund SCSp. managed by PAI Partners completed the acquisition of 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Consensus EPS estimates fall by 34%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

New major risk - Financial position

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Consensus EPS estimates fall by 11%

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 15%

German Fresenius Reportedly Seeks to Sell Vamed Reha

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Consensus EPS estimates increase by 57%

Fresenius SE & Co. KGaA (ETR:FRE) Analysts Just Trimmed Their Revenue Forecasts By 34%

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Consensus revenue estimates decrease by 46%

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

Fresenius SE KGaA (ETR:FRE) Is Reinvesting At Lower Rates Of Return

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

Consensus EPS estimates fall by 14%

New major risk - Financial position

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 14%

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Some Investors May Be Worried About Fresenius SE KGaA's (ETR:FRE) Returns On Capital

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

At €25.59, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Capital Allocation Trends At Fresenius SE KGaA (ETR:FRE) Aren't Ideal

Consensus EPS estimates fall by 17%

Fresenius SE KGaA's (ETR:FRE) Soft Earnings Are Actually Better Than They Appear

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

Full year 2022 earnings: EPS misses analyst expectations

Are Investors Undervaluing Fresenius SE & Co. KGaA (ETR:FRE) By 38%?

Is It Too Late To Consider Buying Fresenius SE & Co. KGaA (ETR:FRE)?

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

These 4 Measures Indicate That Fresenius SE KGaA (ETR:FRE) Is Using Debt Extensively

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Third quarter 2022 earnings released: EPS: €0.57 (vs €0.74 in 3Q 2021)

Should You Investigate Fresenius SE & Co. KGaA (ETR:FRE) At €21.71?

Brookfield Reportedly Drops Out of Race to Buy Healius

The Returns On Capital At Fresenius SE KGaA (ETR:FRE) Don't Inspire Confidence

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Is Fresenius SE KGaA (ETR:FRE) Using Too Much Debt?

Price target decreased to €40.39

Second quarter 2022 earnings: EPS misses analyst expectations

Healius Reportedly Launches Day Surgery Sale Process